#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Systemic scleroderma Anaemia Demyelination Dupuytren's contracture Choroidal dystrophy Prodromal Alzheimer's disease Vulval cancer recurrent Ocular myasthenia Kaposi's sarcoma Nephroblastoma Spinal muscular atrophy Follicular lymphoma Paroxysmal nocturnal haemoglobinuria Scleroderma associated digital ulcer Malignant glioma More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis – Trials in Disease Glomerulonephritis membranoproliferative – Life with Disease Rhabdomyosarcoma recurrent – Diagnostics Amyotrophic lateral sclerosis – Basic Information Epidermolysis bullosa – Life with Disease Hyperoxaluria – Basic Information Glomerulonephritis rapidly progressive – Trials in Disease Metachromatic leukodystrophy Ocular melanoma – Life with Disease Haemophilia A with anti factor VIII More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ALFENTANIL HYDROCHLORIDE Dapagliflozin Propanediol Levodropropizine Phenol NVG-2089 Human Vaccinia Immunoglobulin Dog Epithelia Emactuzumab Gentamicin Sulfate Sar441566 Chlortalidone SIPAVIBART Pabinafusp Alfa BUMETANIDE Patiromer Daridorexant Isosorbide Dinitrate Prilocaine Nacystelyn Zanidatamab More therapies…

    Learn about Your Condition

    Stomatitis Triple positive breast cancer Pancoast's tumour Acute on chronic liver failure Univentricular heart Gastric cancer Biliary cancer metastatic Anal squamous cell carcinoma Large cell lung cancer stage 0 Pyoderma Acute cardiac event Chorea Connective tissue disorder Sickle cell anaemia Renal cell carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik

Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik

ul. Wiejska 81, Bialystok, 15-351, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Etanercept
    Bulgaria Hungary Poland Romania

  • Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    • Jnj-77242113
    France Germany Hungary Italy Poland Spain

  • Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Adalimumab
    • Baricitinib
    • Etanercept
    Austria Belgium Czechia Denmark France Germany +9

  • A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

    Not recruiting

    3 1
    Investigated Diseases:
    • Obesity
    Bulgaria Czechia Germany Hungary Poland Romania +2

  • A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Bulgaria Denmark France Germany Ireland Italy +3

  • A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Dapagliflozin
    • Metformin
    Bulgaria Croatia Czechia Denmark Finland Germany +9

  • A study comparing weekly insulin icodec and semaglutide with daily insulin degludec and insulin aspart in people with type 2 diabetes not well controlled on premixed insulin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Insulin Aspart
    • INSULIN DEGLUDEC
    • Insulin Icodec
    Poland

  • A study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes not well controlled by diet and exercise

    Not recruiting

    3 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Hungary Italy Poland

  • Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Zasocitinib
    Bulgaria Czechia France Germany Greece Hungary +3

  • Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

    Not recruiting

    3 1
    Investigated Diseases:
    • Obesity
    • Overweight
    Investigated Drugs:
    • Cagrilintide
    France Germany Italy Norway Poland
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!